title: Recombinant vaccinia viruses expressing immunoglobulin variable regions efficiently and selectively protect mice against tumoral B-cell growth.
abstract: The variable regions of the immunoglobulin (Ig) expressed on the surface of a malignant B cell can be considered tumor-specific antigens and, as such, could be targets for immunotherapeutic approaches. However, because until now the immunization procedures have been complex and have given only partial protection, it was necessary to find new methods of immunotherapy. Here, we present a successful method of vaccination against B-cell tumors in a murine model. We produced recombinant vaccinia viruses (rVV) expressing the heavy and the light chain of surface Ig of a patient's malignant B cells and we tested the ability of these rVV to protect immunized mice against tumor growth of transfectomas producing the same human Ig. The protection of the mice was complete and specific to the variable region of the immunizing heavy chain although specific lymphoproliferative and cytotoxic responses were not detectable in vitro. The protection was strictly dependent on the presence of CD4 T cells and asialo GM1+ cells. Furthermore, tumor protection clearly required gamma-interferon and was partially inhibited by blocking the Fas-Fas ligand interaction. We also show, in a murine syngeneic model, that rVV expressing a poorly mutated Ig protects against the growth of Ig-producing tumor.
authors.affiliation: Laboratoire d'Immunopathologie, Institut d'Immuno-hématologie, Hôpital Civil, Strasbourg 67091, France.
authors.forename: S
authors.initials: S
authors.lastname: BenAmmar-Ceccoli
authors.forename: S
authors.initials: S
authors.lastname: Humblot
authors.forename: R
authors.initials: R
authors.lastname: Crouzier
authors.forename: B
authors.initials: B
authors.lastname: Acres
authors.forename: M P
authors.initials: MP
authors.lastname: Kieny
authors.forename: D
authors.initials: D
authors.lastname: Herlyn
authors.forename: J L
authors.initials: JL
authors.lastname: Pasquali
authors.forename: T
authors.initials: T
authors.lastname: Martin
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001483:Base Sequence; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D006224:Cricetinae; D005260:Female; D005434:Flow Cytometry; D005677:G(M1) Ganglioside / Q000276:immunology / Q000378:metabolism; D005822:Genetic Vectors; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D007135:Immunoglobulin Variable Region / Q000235:genetics / Q000276:immunology*; D007371:Interferon-gamma / Q000276:immunology / Q000378:metabolism; D016393:Lymphoma, B-Cell / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D009374:Neoplasms, Experimental / Q000378:metabolism / Q000517:prevention & control*; D011994:Recombinant Proteins / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D019014:fas Receptor / Q000276:immunology / Q000378:metabolism
chemical_list: D007130:Immunoglobulin Idiotypes; D007135:Immunoglobulin Variable Region; D011994:Recombinant Proteins; D019014:fas Receptor; D005677:G(M1) Ganglioside; C018835:asialo GM1 ganglioside; D007371:Interferon-gamma